Extracellular vesicles (EVs) are small membrane-bound vesicles released by most cells. They serve as key mediators of cell-to-cell communication and have shown utility in diagnostic and therapeutic applications. A novel class of EVs, similar in size to EVs derived from liquids (urine, blood, cell culture media, etc.), has been discovered natively embedded within the extracellular matrix of soft tissues and in vitro cell sheets. These matrix-bound nanovesicles (MBVs) reveal a potential novel mechanism of cell-environment interactions. Despite their promise as immunomodulatory therapies, MBVs remain critically understudied. They have yet to be isolated from stem cells and characterized for markers and qualities, and it remains unclear whether they are characteristically different from other matrix-resident vesicles such as matrix vesicles and migrasomes.
Researchers at the University of California, Santa Barbara have created a novel method to isolate and confirm the presence of matrix-bound nanovesicles (MBVs) naturally secreted and embedded within extracellular matrix produced by cells grown in vitro. Unlike commonly studied exosomes derived from body fluids or conditioned media, MBVs are trapped within the extracellular matrix deposited by high-density stem cell cultures and can be selectively released using enzymatic digestion and purified by size exclusion chromatography. The isolated MBVs exhibit distinct size, surface proteins, and characteristics including enhanced CD63 expression and unique protein profiles compared to traditional extracellular vesicles. This technology enables detailed study and therapeutic exploitation of MBVs, which have demonstrated immunomodulatory potential and promise for tissue repair applications.
vesicles, EVs, nanovesicles, matrix-bound nanovesicles, MBVs, exosomes, diagnostics, stem cell research, pharmaceuticals, biomaterials, drug delivery